Showing 4821-4830 of 10254 results for "".
- World Vitiligo Day: Ra Medical Highlights Potential of Technologyhttps://practicaldermatology.com/news/world-vitiligo-day-pharos-highlights-potential-of-technology/2457715/In light of World Vitiligo Day (June 25), it’s important to realize that hope is here for patients who suffer from this disease, says Ra Medical Systems. Painless treatment is a possibility with P
- FDA Grants Priority Review for Genentech's Rituxan for Pemphigus Vulgarishttps://practicaldermatology.com/news/fda-grants-priority-review-for-genentechs-rituxan-for-pemphigus-vulgaris/2457883/The FDA has accepted Genentech’s Supplemental Biologics License Application (sBLA) and granted Priority Review for the use of Rituxan (rituximab) for the treatment of pemphigus vulgaris (PV). Genentech is a member of the Roche Group. <
- Zylö Therapeutics: Adam Friedman, MD to Present Data at AAD Annual Meetinghttps://practicaldermatology.com/news/zyl-therapeutics-adam-friedman-md-to-present-data-at-aad-annual-meeting/2457886/Zylö Therapeutics, a nanotechnology-based biopharmaceutical company dedicated to bringing innovative technologies to multiple facets of medicine, announced that preclinical data, utilizing Zylö’s patented hydrogel-derived Na
- Meet TempSure™ Envi from Hologic's Cynosure Divisionhttps://practicaldermatology.com/news/meet-tempsure-envi-from-hologics-cynosure-division/2457915/Hologic's Cynosure division is launching TempSure™ Envi – an FDA-cleared advanced radiofrequency device. TempSure™ Envi heats the deep layers of skin to regenerate collagen and impro
- AI in Action: New Machine Learning Technique May Enhance Computer-aided Diagnosis of Melanomahttps://practicaldermatology.com/news/ai-in-action-new-machine-learning-technique-may-enhance-computer-aided-diagnosis-of-melanoma/2457963/Researchers at Florida Atlantic University’s College of Engineering and Computer Science have developed a technique using machine learning – a sub-field of artificial intelligence (AI) – that will enha
- FDA Approves Janssen's Golimumab for PsA, AShttps://practicaldermatology.com/news/fda-approved-jansens-golimumab-for-psa-as/2457998/The FDA approved Janssen’s SIMPONI ARIA (golimumab) for the treatment of adults with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Simponi is the only fully-human anti-tumor necrosis factor (TNF
- Five ASDS Members Receive President's Awards at Annual Meetinghttps://practicaldermatology.com/news/five-asds-members-receive-presidents-awards-at-annual-meeting/2458024/Five members of the American Society for Dermatologic Surgery (ASDS) received President’s Awards for their contributions to the Society and dermatologic specialty at the 2017 ASDS Annual Meeting in Chicago. The 2017 recipients were Murad Alam, MD,
- Two Galderma Rosacea Therapies Work Well Togetherhttps://practicaldermatology.com/news/two-galderma-rosacea-therapies-work-well-together/2458061/Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCe
- FDA Greenlights Humira Biosim Cyltezo for Multiple Inflammatory Diseaseshttps://practicaldermatology.com/news/fda-greenlights-humira-biosim-cyltezo-for-multiple-inflammatory-diseases/2458073/The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim Pharmaceuticals, Inc.’s Cyltezo™, a biosimilar to Humira®, in a pre-filled syringe for the treatment of multiple chronic inflammatory diseases, including:
- Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in EBhttps://practicaldermatology.com/news/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-eb/2458075/The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to the Abeona Therapeutics Inc.’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. EB-101 is an autologous,&